RxDoctor Payments Data

Elisa Gordon Perez Mena, MD

General Practice · Poinciana, FLNPI 1720680887

Payments from drug & device makers

$869in general payments, 2019–2025

Across 21 payments — averaging $41.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$234
  • Novo Nordisk$204
  • Johnson & Johnson$133
  • AbbVie$121
  • Exact Sciences$49
  • Boehringer Ingelheim$38
  • plus $90 from 4 others

What the payments were for

  • Food & beverage$869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$869 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$5,810
Medicare patients
16
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$40,593
OzempicSemaglutide14$24,405
JardianceEmpagliflozin20$18,086
FarxigaDapagliflozin Propanediol15$17,014
SymbicortBudesonide/Formoterol Fumarate27$9,156
Combivent RespimatIpratropium/Albuterol Sulfate12$5,658
Rosuvastatin Calcium176$2,204
Atorvastatin Calcium212$2,009
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,918
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$1,848
Losartan Potassium153$1,420
Albuterol Sulfate HfaAlbuterol Sulfate72$1,388
Wixela InhubFluticasone Propion/Salmeterol13$1,258
Levothyroxine Sodium116$1,171
Gabapentin59$1,006

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$234$26,17142 claims
Novo NordiskOzempic$204$24,40514 claims
Boehringer IngelheimJardiance, Combivent Respimat$38$23,74432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Poinciana

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →